Pharma News | Biotech News | Global Pharma

With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.

How it helps

Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.

With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.

How it works

Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.

Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.

Start a free trial

Scrip

Chinese Biotechs Join COVID-19 Treatment Race With Repurposed Cancer Drugs

By Dexter Yan 18 Aug 2021

SC2108_China_COVID_Androgen_2BJ9T6J_1200

Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 16 Aug 2021

In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.

Datamonitor Healthcare, Biomedtracker, Scrip

2021 Post-ASCO Insights and Analysis

11 Aug 2021

The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

Scrip

Alzheimer’s Disease: Many Failures Before One Success

By Mandy Jackson 10 Aug 2021

For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been.

Scrip

Oncology, Cell Therapy Developers Bag $175m In China

By Dexter Yan 10 Aug 2021

Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 09 Aug 2021

In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

Scrip

Novavax Pins COVID-19 Hopes On Ex-US, Booster Markets

By Alaric DeArment 06 Aug 2021

The company is planning to file with regulators in the UK, EU, Canada, Australia and New Zealand, with an emphasis on booster shots in developed markets.

Scrip

Canadian Biotech Takes COVID-19 Nasal Spray To Asia Via Glenmark

By Anju Ghangurde 03 Aug 2021

Glenmark hopes to launch SaNOtize’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets. Can the self-administered product impact market dynamics positioned as the first line of defense against COVID-19?

Scrip

Back To The Day Job? AstraZeneca’s Pangalos Looks Ahead To A Post-Pandemic Pipeline

By Andrew McConaghie 03 Aug 2021

Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 25 Jul 2021

In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.

Scrip

Where To Start Tackling ‘Long Covid’? PureTech Pioneers Lung Drug Trial

By Andrew McConaghie 22 Jul 2021

PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery

Scrip

Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing

By Kevin Grogan 21 Jul 2021

Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.

Scrip

Claims Stream In Under COVAX No-Fault Compensation Program

By Anju Ghangurde 07 Jul 2021

SC2107_compensationclaims_F3YYB6_1200x675

The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.

Scrip

10 US Approval Decisions To Look Out For In Q3

By Alex Shimmings 05 Jul 2021

This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 05 Jul 2021

In this week's podcast edition of Five Must-Know Things: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic’s possible effect on regulatory pathways.

Scrip: industry news and insights

​Go behind the headlines

What's included

Below are the Feature List

Follow market developments

Go beyond the news

Hear from news makers

Ask the expert

Pharma Intelligence: latest

Latest headlines

Meet the team

Below are the Analyst Profile

Brenda Sandburg

Editor, Senior Editor

Cathy Kelly

Editor, Senior editor

Denise Peterson

Management, Editor In Chief, Pharma US

How we've helped other businesses

Related Products

Datamonitor Healthcare: data analysis and insight

Trialtrove: gold standard clinical trials intelligence

Biomedtracker: see the drug development process through analysts’ eyes

Next steps

This is Contactus Section

Request a Trial

Client Services

Pharma Report Store

Go behind the headlines